American Renal Associates IPO Prices At $22

American Renal Associates Holdings Inc. (Pending:ARA) priced its 7.5 million share IPO @ $22.00, within the anticipated range ($20-23), raising $165 million in proceeds. The company will have a market capitalization of approximately $678M (assuming the option to purchase additional shares is exercised).

 

For full article: http://seekingalpha.com/article/3966818-american-renal-associates-ipo-prices-22

Posted in Uncategorized | Leave a comment

MGM Growth Properties Prices IPO At High End Of Anticipated Range

MGM Growth Properties LLC (Pending:MGP) priced their 50 million share IPO @ $21.00, the top of the anticipated range, raising $1.05 billion. The offering is led by joint bookrunning managers BofA Merrill Lynch, J.P. Morgan, Morgan Stanley, Evercore ISI, Barclays, Citigroup, and Deutsche Bank Securities.

For full article: http://seekingalpha.com/article/3966543-mgm-growth-properties-prices-ipo-high-end-anticipated-range

Posted in Uncategorized | Leave a comment

BATS Looks To Ignite The U.S. IPO Market

BATS Global Markets, Inc. (Pending:BATS) priced its upsized 13.3 million share IPO @ $19.00, the top of the anticipated range. The company raised $252.7 million, and will have a market cap of approximately $1.82 billion.

 

For full article: http://seekingalpha.com/article/3965609-bats-looks-ignite-u-s-ipo-market

Posted in Uncategorized | Leave a comment

U.S. IPO Market In Desperate Need Of Some Oxygen After Q1

First quarter 2016 was the slowest quarter for U.S. IPOs since Q1 2009 (when there was just 1 IPO in Q1, and the world was about to implode). There were just 7 offerings, all in Healthcare, representing approximately $623 million in proceeds. This compares to the same quarter in 2015, in which there were 31 offerings raising approximately $4.87 billion in proceeds.

For full article: http://seekingalpha.com/article/3964670-u-s-ipo-market-desperate-need-oxygen-q1

Posted in Uncategorized | Leave a comment

First IPO Of Q2 Closes Below Issue

Aeglea BioTherapeutics Inc. (Pending:AGLE) opened flat and closed at $9.77 in its IPO debut Thursday. The company priced the upsized 5 million share IPO at $10.00, well below the indicated range of $16.00-$18.00. All of the shares being sold are primary shares that the company intends to use:

For full article: http://seekingalpha.com/article/3964007-first-ipo-q2-closes-issue

Posted in Uncategorized | Leave a comment

The Year To Date IPO Performance Of U.S. Listed China-Based Companies Looks Positive For Alibaba

With the largest and most anticipated U.S. listed IPO of the year now trading, Alibaba Group Holding Limited (BABA: NYSE), here is a look at the performance of the all the 2014 U.S. IPO’s of China based companies to date:

http://seekingalpha.com/article/2508325-the-year-to-date-ipo-performance-of-u-s-listed-china-based-companies-looks-positive-for-alibaba

Posted in Uncategorized | Leave a comment

7 IPOs expected for the week 9/15

With all eyes focused on the much anticipated end of the week offering of Alibaba, there are 6 additional companies quietly expecting to make their debuts this week:

Civitas Solutions, Inc. (CIVI:NYSE) is the leading national provider of home- and community-based health and human services to must-serve individuals with intellectual, developmental, physical or behavioral disabilities and other special needs. The company is offering 11.7M shares @ $20.00-23.00.  The offering is led by Barclays, BAML, and UBS.

* Update: they priced 11.7M shares @ $17.00, well below the range.

Tokai Pharmaceuticals Inc. (TKAI:NSDQ) is a clinical-stage biopharmaceutical company focused on developing novel proprietary therapies for the treatment of prostate cancer and other hormonally-driven diseases.  They are offering 5.4M shares @ $13-15.  The offering is led by BMO Capital Markets, Stifel, and William Blair.

*Update: they priced an upsized 6.48M shares @ $15.00, the high end of the range.

rEVO Biologics, Inc. (RBIO: NSDQ) is a commercial-stage biopharmaceutical company focused on the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions.  They are offering 3.6M shares @ $13.00-15.00.  The offering is led by Piper Jaffray and Guggenheim Securities.

*Update: the offering has been postponed and may come some time next week.

Foamix Pharmaceuticals Ltd. (FOMX: NSDQ) is  a clinical-stage specialty pharmaceutical company focused on developing and commercializing our proprietary minocycline foam for the treatment of acne, impetigo and other skin conditions.  The company is offering 5.91M shares @ $10.00-12.00.  The offering is led by Barclays and Cowen & Company.

ProQR Therapeutics B.V. (PRQR: NSDQ) is an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis, or CF.  They are offering 6.25M shares @ $11.00-13.00.  The offering is led by Leerink Partners and Deutsche Bank.

 Viking Therapeutics, Inc. (VKTX: NSDQ) is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  They are offering 5M shares @ $10.00-12.00.  The offering is being led by Oppenheimer & Co. and Roth Capital Partners.

Last but not least….

Alibaba Group Holding Limited (BABA: NYSE) is the largest online and mobile commerce company in the world in terms of gross merchandise volume in 2013, according to the IDC GMV Report. They operate their ecosystem as a platform for third parties, and they do not engage in direct sales, compete with their merchants or hold inventory.  The company is offering 320M shares @ $60-66, which would be a market cap of approx $170B at the high end of the range.  The offering is being led by Credit Suisse, Deutsche Bank, Goldman, JP Morgan, Morgan Stanley, and Citigroup.

*Update: Due to high demand, the range has been increased to $66-68.

Posted in IPO | Tagged , , , , , , , | Leave a comment